<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850460</url>
  </required_header>
  <id_info>
    <org_study_id>PAM-0655</org_study_id>
    <nct_id>NCT00850460</nct_id>
  </id_info>
  <brief_title>Quality of Life in Patients With Statin-Associated Myopathy</brief_title>
  <official_title>Quality of Life and Metabolic Alterations in Patients With Statin-Associated Myopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Adelphi University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will focus on possible effects of statins on muscle strength and why they&#xD;
      become tired more easily, quality of life, and measurements to understand why muscles are not&#xD;
      able to fully utilize fats. The investigators are specifically interested in statin users and&#xD;
      the impact of muscle symptoms on daily activities and quality of life.&#xD;
&#xD;
      This study hypothesize that patients with likely statin-associated myopathy have a metabolic&#xD;
      dysregulation in fuel utilization such that compared to patients continuing statins, those on&#xD;
      placebo will show:&#xD;
&#xD;
        1. improved Individualized Neuromuscular Quality of Life (INQoL) and Short Form-36 (SF-36)&#xD;
           scores (primary end point)&#xD;
&#xD;
        2. alleviation of muscle symptoms,&#xD;
&#xD;
        3. increased utilization of fatty acids as a fuel source reflected by the metabolic test&#xD;
           results&#xD;
&#xD;
        4. decreased intramyocellular lipid (IMCL)&#xD;
&#xD;
        5. improved insulin sensitivity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will focus on possible effects of statins on muscle strength and quality&#xD;
      of life, and measurements to understand why muscles of statin users are not able to fully&#xD;
      utilize fats. The investigators are specifically interested in statin users and the impact of&#xD;
      muscle symptoms on daily activities and quality of life.&#xD;
&#xD;
      This study hypothesizes that patients with likely statin-associated myopathy have a metabolic&#xD;
      dysregulation in fuel utilization such that compared to patients continuing statins, those on&#xD;
      placebo will show:&#xD;
&#xD;
        1. improved INQoL and SF-36 scores (primary end point)&#xD;
&#xD;
        2. alleviation of muscle symptoms,&#xD;
&#xD;
        3. increased utilization of fatty acids as a fuel source reflected by the metabolic test&#xD;
           results&#xD;
&#xD;
        4. decreased IMCL&#xD;
&#xD;
        5. improved insulin sensitivity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator left institution and no PI has been found to continue the study&#xD;
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individualized Neuromuscular Quality of Life (INQoL) Mean Scores From Week 0 to Week 8</measure>
    <time_frame>Week 0 to Week 8</time_frame>
    <description>Scores from the self-administered INQoL questionnaire will be compared at the start of the study (Week 0) and at the end (Week 8) between the statin-treated group and the placebo group. Scores range from 0-100, with 100 being a better outcome. Measures reported are the means of Week 0 and week 8, measures of dispersion is the range of the results (3 per group).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Individualized Short Form-36 (SF-36) Mean Scores (Physical Component) From Week 0 to Week 8</measure>
    <time_frame>Week 0 to Week 8</time_frame>
    <description>Scores from the self-administered SF-36 (Physical component) questionnaire were measured at the start (Week 0) of the study and at the end (Week 8) among patients in the placebo- and statin-treated group. Mean scores range from 0 (minimum) - 100 (maximum) with higher mean scores reflecting better outcomes. Measures reported are the means of Week 0 and week 8, measures of dispersion is the range of scores.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Statin Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactose placebo pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Statins</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Statin medications</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statins</intervention_name>
    <description>Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.</description>
    <arm_group_label>Statins</arm_group_label>
    <other_name>atorvastatin, simvastatin, pravastatin, rosuvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pills will consist of lactose and will be given one capsule once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>lactose pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  males and females 30-60 yrs old&#xD;
&#xD;
          -  experiencing muscle pain, weakness, numbness or cramping that they perceive to&#xD;
             interfere with activities of daily living (ADLs), but able to ambulate independently&#xD;
             (in order to perform exercise tests)&#xD;
&#xD;
          -  muscle symptoms started/ occurred within one year of starting statin treatment or&#xD;
             within one year of changing statin brand or dose adjustment&#xD;
&#xD;
          -  currently taking a statin (has been taking medications ≥ 80% of the time or at least 5&#xD;
             days/week)&#xD;
&#xD;
          -  ≤ 15% probability of having a cardiovascular (CV) event in the next 10 years&#xD;
             calculated using an online CV risk calculator (while on current statin) for the&#xD;
             questionnaire portion; AND with a low or a moderate American College of Sports&#xD;
             Medicine (ACSM) risk stratification for a cardiovascular event during a treadmill test&#xD;
             for the full metabolic study&#xD;
&#xD;
          -  must agree to have a letter sent to inform the health care provider who prescribed the&#xD;
             statin of study participation except for subjects referred by Metropolitan Hospital&#xD;
             physicians&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  concomitant treatment with other lipid-lowering agents&#xD;
&#xD;
          -  impaired liver or kidney function ( alanine aminotransferase (ALT) or asparate&#xD;
             aminotransferase (AST) ≥ 3x upper limit of normal, creatinine ≥ 3x or creatine&#xD;
             phosphokinase (CPK) ≥ 5x upper limit of normal)&#xD;
&#xD;
          -  untreated hypo or hyperthyroidism&#xD;
&#xD;
          -  current treatment with other medications known to increase risk of myopathy (e.g.&#xD;
             cyclosporine, azithromycin, erythromycin and other macrolide antibiotics, azole&#xD;
             antifungals, fusidic acid, digoxin)&#xD;
&#xD;
          -  documented history of muscle disorder or myopathy other than statin-associated&#xD;
             myopathy&#xD;
&#xD;
          -  anemia (Hb&lt; 110 g/dL)&#xD;
&#xD;
          -  cancer within 5 years of enrollment except basal or squamous cell carcinoma (CA) of&#xD;
             the skin&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  Uncontrolled blood pressure ≥ 160/100&#xD;
&#xD;
          -  known coronary artery disease or peripheral vascular disease&#xD;
&#xD;
          -  chronic illnesses such as lupus, rheumatoid arthritis, psoriasis&#xD;
&#xD;
          -  any condition, that at the investigators' discretion would impact/ bias the study data&#xD;
&#xD;
          -  long term oral, nasal, or inhaler steroid use &gt; 6 months&#xD;
&#xD;
          -  on Hormone Therapy except for thyroid replacement&#xD;
&#xD;
          -  alcohol consumption ≥ 40 g/day (3 glasses/day wine or beers or binge drinking ≥ 4&#xD;
             glasses/night)&#xD;
&#xD;
          -  engaged in significant amounts of sport or strenuous leisure activity (&gt; 60 min four&#xD;
             times per week)&#xD;
&#xD;
          -  surgery in the past 6 months except for minor excision/incision procedures,&#xD;
&#xD;
          -  12-L electrocardiogram demonstrating old/new myocardial infarction/ ischemia or other&#xD;
             findings that, at the cardiologist's discretion, may put the subject at high risk&#xD;
&#xD;
          -  cognitive impairment that prevents comprehension of questionnaires&#xD;
&#xD;
          -  inability to read English (questionnaire language)&#xD;
&#xD;
        Exclusions for the metabolic study:&#xD;
&#xD;
          -  currently taking beta blockers&#xD;
&#xD;
          -  body mass index &gt; 28 kg/m2&#xD;
&#xD;
          -  premenopausal females &lt; 50 yrs (menopause defined as 12 consecutive months without&#xD;
             menstruation (in order to avoid the confounding effect of the menstrual cycle phase on&#xD;
             fuel selection)&#xD;
&#xD;
          -  physical disability or previous injury that prevents safe exercise testing&#xD;
&#xD;
          -  do not meet the magnetic resonance spectroscopy (MRS) prescreening criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia D Maningat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>February 23, 2009</study_first_submitted>
  <study_first_submitted_qc>February 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2009</study_first_posted>
  <results_first_submitted>February 12, 2016</results_first_submitted>
  <results_first_submitted_qc>September 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2016</results_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Advertisements were placed (internet, radio, print) and a screening phone questionnaire was administered by study staff to determine potential inclusion. A collaboration with the Metropolitan Hospital (NY) was also established for potential referrals.</recruitment_details>
      <pre_assignment_details>Subjects in whom statins are possibly causative, using the World Health Organization (WHO)-Causality Assessment form, were invited to the outpatient clinic for 2 screening visits. Subjects found to be at high risk for cardiovascular events and those unwilling to be shifted to placebo were not enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Lactose placebo pill&#xD;
Placebo: Placebo pills will consist of lactose and will be given one capsule once daily</description>
        </group>
        <group group_id="P2">
          <title>Statins</title>
          <description>Statin medications&#xD;
Statins: Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started - Week 0</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completion - Week 8</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Males and females 30-60 years old, taking a statin, experiencing muscle pain, weakness, cramping and not at high risk for a cardiovascular event</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Lactose placebo pill&#xD;
Placebo: Placebo pills will consist of lactose and will be given one capsule once daily</description>
        </group>
        <group group_id="B2">
          <title>Statins</title>
          <description>Statin medications&#xD;
Statins: Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Individualized Neuromuscular Quality of Life (INQoL) Mean Scores From Week 0 to Week 8</title>
        <description>Scores from the self-administered INQoL questionnaire will be compared at the start of the study (Week 0) and at the end (Week 8) between the statin-treated group and the placebo group. Scores range from 0-100, with 100 being a better outcome. Measures reported are the means of Week 0 and week 8, measures of dispersion is the range of the results (3 per group).</description>
        <time_frame>Week 0 to Week 8</time_frame>
        <population>Three patients from each group completed the questionnaire portion of the study at Week 0 and Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Lactose placebo pill&#xD;
Placebo: Placebo pills will consist of lactose and will be given one capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Statins</title>
            <description>Statin medications&#xD;
Statins: Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Individualized Neuromuscular Quality of Life (INQoL) Mean Scores From Week 0 to Week 8</title>
          <description>Scores from the self-administered INQoL questionnaire will be compared at the start of the study (Week 0) and at the end (Week 8) between the statin-treated group and the placebo group. Scores range from 0-100, with 100 being a better outcome. Measures reported are the means of Week 0 and week 8, measures of dispersion is the range of the results (3 per group).</description>
          <population>Three patients from each group completed the questionnaire portion of the study at Week 0 and Week 8.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 Mean Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="43.9" upper_limit="95"/>
                    <measurement group_id="O2" value="76" lower_limit="67.2" upper_limit="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 Mean Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="53.3" upper_limit="88.3"/>
                    <measurement group_id="O2" value="50" lower_limit="43.9" upper_limit="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Individualized Short Form-36 (SF-36) Mean Scores (Physical Component) From Week 0 to Week 8</title>
        <description>Scores from the self-administered SF-36 (Physical component) questionnaire were measured at the start (Week 0) of the study and at the end (Week 8) among patients in the placebo- and statin-treated group. Mean scores range from 0 (minimum) - 100 (maximum) with higher mean scores reflecting better outcomes. Measures reported are the means of Week 0 and week 8, measures of dispersion is the range of scores.</description>
        <time_frame>Week 0 to Week 8</time_frame>
        <population>Three patients from each group completed the questionnaire portion of the study at Week 0 and Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Lactose placebo pill&#xD;
Placebo: Placebo pills will consist of lactose and will be given one capsule once daily</description>
          </group>
          <group group_id="O2">
            <title>Statins</title>
            <description>Statin medications&#xD;
Statins: Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Individualized Short Form-36 (SF-36) Mean Scores (Physical Component) From Week 0 to Week 8</title>
          <description>Scores from the self-administered SF-36 (Physical component) questionnaire were measured at the start (Week 0) of the study and at the end (Week 8) among patients in the placebo- and statin-treated group. Mean scores range from 0 (minimum) - 100 (maximum) with higher mean scores reflecting better outcomes. Measures reported are the means of Week 0 and week 8, measures of dispersion is the range of scores.</description>
          <population>Three patients from each group completed the questionnaire portion of the study at Week 0 and Week 8.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 Mean Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="45.7" upper_limit="58"/>
                    <measurement group_id="O2" value="53" lower_limit="49.7" upper_limit="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 Mean Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="53.8" upper_limit="58.6"/>
                    <measurement group_id="O2" value="48" lower_limit="47.3" upper_limit="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from the time the subjects were enrolled in the study until study termination (eight weeks). The study ran for two years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Lactose placebo pill&#xD;
Placebo: Placebo pills will consist of lactose and will be given one capsule once daily</description>
        </group>
        <group group_id="E2">
          <title>Statins</title>
          <description>Statin medications&#xD;
Statins: Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>The Rockefeller University Center for Clinical and Translational</organization>
      <phone>212 327-8408</phone>
      <email>trinnamaningatmd@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

